Informace o publikaci

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

Autoři

FIALA Ondrej VESKRNOVA Veronika CHLOUPKOVÁ Renata POPRACH Alexandr KISS Igor KOPECKOVA Katerina DUŠEK Ladislav SLAVICEK Lubomir KOHOUTEK Milan FINEK Jindrich SVOBODA Marek PETRUZELKA Lubos BOUBLIKOVA Ludmila DVORAK Josef MELICHAR Bohuslav BUCHLER Tomas

Druh Článek v odborném periodiku
Časopis / Zdroj Targeted Oncology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1007/s11523-018-0597-7
Klíčová slova Anti-EGFR Monoclonal Antibodies; Colorectal Cancer
Popis BackgroundThe addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results.ObjectiveTo determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens.Patients and MethodsClinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n=401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n=71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n=101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle.ResultsThree hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9months (95% CI 28.6-47.3) for cohort C, respectively.ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.